Proton pump inhibitor and clopidogrel interaction: The case for watchful waiting

被引:3
作者
Tan, Victoria P. [1 ]
Yan, Bryan P. [2 ]
Hunt, Richard H. [3 ]
Wong, Benjamin C. Y. [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China
[3] McMaster Univ, Farncombe Family Digest Dis Res Inst, Div Gastroenterol, Hlth Sci Ctr, Hamilton, ON, Canada
关键词
clopidogrel; gastro-intestinal bleeding; proton pump inhibitors; GASTRIC-ACID PUMP; ANTIPLATELET THERAPY; CYTOCHROME-P450; 3A; CLINICAL-OUTCOMES; DRUG-INTERACTION; CONCOMITANT USE; RISK; PHARMACOKINETICS; IMPACT; OMEPRAZOLE;
D O I
10.1111/j.1440-1746.2010.06366.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Clopidogrel is an integral part of the management of several important vascular diseases. However the medium to long term clinical outcomes are poorer for these patients if they experience gastro-intestinal bleeding, hence patients with risk factors for gastro-intestinal bleeding are frequently prescribed proton pump inhibitors. Conflicting evidence exists as to the existence of an adverse interaction between clopidogrel and proton pump. This review examines the original studies, which suggested the adverse interaction, the subsequent and most recent studies, the pharmaco-dynamics of the two drugs and suggests an algorithm for the use of clopidogrel with proton pump inhibitors.
引用
收藏
页码:1342 / 1347
页数:6
相关论文
共 50 条
[1]  
ALLEN JM, CMAJ, V180, P1228
[2]  
Aubert RE, 2008, CIRCULATION, V118, pS815
[3]   Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents [J].
Besancon, M ;
Simon, A ;
Sachs, G ;
Shin, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (36) :22438-22446
[4]   ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents [J].
Bhatt, Deepak L. ;
Scheiman, James ;
Abraham, Neena S. ;
Antman, Elliott M. ;
Chan, Francis K. L. ;
Furberg, Curt D. ;
Johnson, David A. ;
Mahaffey, Kenneth W. ;
Quigley, Eamonn M. ;
Harrington, Robert A. ;
Bates, Eric R. ;
Bridges, Charles R. ;
Eisenberg, Mark J. ;
Ferrari, Victor A. ;
Hlatky, Mark A. ;
Kaul, Sanjay ;
Lindner, Jonathan R. ;
Moliterno, David J. ;
Mukherjee, Debabrata ;
Schofield, Richard S. ;
Rosenson, Robert S. ;
Stein, James H. ;
Weitz, Howard H. ;
Wesley, Deborah J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (18) :1502-1517
[5]  
BHATT DL, 2009, COGENT PROSPECTIVE R
[6]  
*CAN AG DRUGS TECH, 2008, PROT PUMP INH
[7]   The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin [J].
Clarke, TA ;
Waskell, LA .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (01) :53-59
[8]  
COHEN M, 2009, CATHETER CARDIOVASC, V2, P2
[9]   Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study [J].
Collet, Jean-Philippe ;
Hulot, Jean-Sebastien ;
Pena, Anna ;
Villard, Eric ;
Esteve, Jean-Baptiste ;
Silvain, Johanne ;
Payot, Laurent ;
Brugier, Delphine ;
Cayla, Guillaume ;
Beygui, Farzin ;
Bensimon, Gilbert ;
Funck-Brentano, Christian ;
Montalescot, Gilles .
LANCET, 2009, 373 (9660) :309-317
[10]   Clopidogrel [J].
Coukell, AJ ;
Markham, A .
DRUGS, 1997, 54 (05) :745-750